Mycobacteria-specific T cells may be expanded from healthy donors and are near absent in primary immunodeficiency disorders
Frontiers in Immunology, ISSN: 1664-3224, Vol: 10, Issue: MAR, Page: 621
2019
- 4Citations
- 11Usage
- 38Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations4
- Citation Indexes4
- Usage11
- Abstract Views11
- Captures38
- Readers38
- 38
Article Description
Mycobacterial Infections can be severe in patients with T-cell deficiency or phagocyte disorders, and treatment is frequently complicated by antimicrobial resistance. Restoration of T-cell immunity via stem cell transplantation facilitates control of mycobacterial infections, but presence of active infections during transplantation is associated with a higher risk of mortality. Adoptive T cell immunotherapy has been successful in targeting viruses, but has not been attempted to treat mycobacterial infections. We sought to expand and characterize mycobacterial-specific T-cells derived from healthy donors in order to determine suitability for adoptive immunotherapy. Mycobacteria-specific T-cells (MSTs) were generated from 10 healthy donors using a rapid ex vivo expansion protocol targeting five known mycobacterial target proteins (AG85B, PPE68, ESXA, ESXB, and ADK). MSTs were compared to T-cells expanded from the same donors using lysate from M. tuberculosis or purified protein derivative from M. avium (sensitin). MST expansion from seven patients with primary immunodeficiency disorders (PID) and two patients with IFN-γ autoantibodies and invasive M. avium infections. MSTs expanded from healthy donors recognized a median of 3 of 5 antigens, with production of IFN-γ, TNF, and GM-CSF in CD4+ T cells. Comparison of donors who received BCG vaccine (n = 6) to those who did not (n = 4) showed differential responses to PPE68 (p = 0.028) and ADK (p = 0.015) by IFN-γ ELISpot. MSTs expanded from lysate or sensitin also recognized multiple mycobacterial antigens, with a statistically significant differences noted only in the response to PPE68 (p = 0.016). MSTs expanded from patients with primary immunodeficiency (PID) and invasive mycobacterial infections showed activity against mycobacterial antigens in only two of seven subjects, whereas both patients with IFN-γ autoantibodies recognized mycobacterial antigens. Thus, MSTs can be generated from donors using a rapid expansion protocol regardless of history of BCG immunization. Most tested PID patients had no detectable T-cell immunity to mycobacteria despite history of infection. MSTs may have clinical utility for adoptive immunotherapy in T-cell deficient patients with invasive mycobacterial infections.
Bibliographic Details
10.3389/fimmu.2019.00621; 10.3389/fimmu.2019.00621.s005; 10.3389/fimmu.2019.00621.s009; 10.3389/fimmu.2019.00621.s004; 10.3389/fimmu.2019.00621.s002; 10.3389/fimmu.2019.00621.s001; 10.3389/fimmu.2019.00621.s003; 10.3389/fimmu.2019.00621.s008; 10.3389/fimmu.2019.00621.s007; 10.3389/fimmu.2019.00621.s006
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85064853063&origin=inward; http://dx.doi.org/10.3389/fimmu.2019.00621; http://www.ncbi.nlm.nih.gov/pubmed/30984189; https://www.frontiersin.org/articles/10.3389/fimmu.2019.00621/supplementary-material/10.3389/fimmu.2019.00621.s005; http://dx.doi.org/10.3389/fimmu.2019.00621.s005; https://www.frontiersin.org/articles/10.3389/fimmu.2019.00621/supplementary-material/10.3389/fimmu.2019.00621.s009; http://dx.doi.org/10.3389/fimmu.2019.00621.s009; https://www.frontiersin.org/articles/10.3389/fimmu.2019.00621/supplementary-material/10.3389/fimmu.2019.00621.s004; http://dx.doi.org/10.3389/fimmu.2019.00621.s004; https://www.frontiersin.org/article/10.3389/fimmu.2019.00621/full; https://www.frontiersin.org/articles/10.3389/fimmu.2019.00621/supplementary-material/10.3389/fimmu.2019.00621.s002; http://dx.doi.org/10.3389/fimmu.2019.00621.s002; https://www.frontiersin.org/articles/10.3389/fimmu.2019.00621/supplementary-material/10.3389/fimmu.2019.00621.s001; http://dx.doi.org/10.3389/fimmu.2019.00621.s001; https://www.frontiersin.org/articles/10.3389/fimmu.2019.00621/supplementary-material/10.3389/fimmu.2019.00621.s003; http://dx.doi.org/10.3389/fimmu.2019.00621.s003; https://www.frontiersin.org/articles/10.3389/fimmu.2019.00621/supplementary-material/10.3389/fimmu.2019.00621.s008; http://dx.doi.org/10.3389/fimmu.2019.00621.s008; https://www.frontiersin.org/articles/10.3389/fimmu.2019.00621/supplementary-material/10.3389/fimmu.2019.00621.s007; http://dx.doi.org/10.3389/fimmu.2019.00621.s007; https://www.frontiersin.org/articles/10.3389/fimmu.2019.00621/supplementary-material/10.3389/fimmu.2019.00621.s006; http://dx.doi.org/10.3389/fimmu.2019.00621.s006; https://hsrc.himmelfarb.gwu.edu/smhs_peds_facpubs/3013; https://hsrc.himmelfarb.gwu.edu/cgi/viewcontent.cgi?article=4015&context=smhs_peds_facpubs; https://dx.doi.org/10.3389/fimmu.2019.00621; https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.00621/full; https://www.frontiersin.org/articles/10.3389/fimmu.2019.00621/pdf; https://www.frontiersin.org/articles/10.3389/fimmu.2019.00621/full
Frontiers Media SA
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know